drugset / Trial / NCT03206021

COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors

NCT03206021 ↗

Phase 1 Completed 31 enrolled The Hospital for Sick Children
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Many pediatric brain and solid tumors have altered epigenetic landscapes, and altered DNA methylation. As such this study is a Phase I/Ib study of combined 5'Azacitidine with an escalating dose of carboplatin for all recurrent/refractory pediatric brain and solid tumors. The phase I component will establish with maximum tolerated dose of carboplatin with azacytidine. An expansion cohort will be recruited of up to 30 patients will follow consisting of 20 recurrent posterior fossa ependymoma and 10 recurrent supratentorial ependymoma.

Timeline

Start
2017-08-01
Primary completion
2022-08-31
Completion
2024-03-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject 5-Azacytidine Small molecule 50 mg/m2 —
Subject 5-Azacytidine Small molecule 75 mg/m2 —
Subject Carboplatin Small molecule 3 unknown —
Subject Carboplatin Small molecule 4 unknown —
Subject Carboplatin Small molecule 6 unknown —